Small-cell carcinomas and high-grade squamous cell carcinomas must be, due to the different clinical features, differentiated by neuroendocrine markers (synaptophysin/chromogranin A) and a squamous-basal marker (e.g., p40) expression. This evidence concerns the gene CHGA and squamous cell carcinoma.